In particular, CD47 is an immune checkpoint molecule that can inhibit phagocytosis of cancer cells by tumor-associated macrophages (TAMs), and CD47 blockade has been found to synergize with chemotherapy cabazitaxel in preclinical models of TNBC (Cao et al., 2021). Here, CD47 is linked to cancer.